- Home
- CNTB vs MAIA Comparison
CNTB vs MAIA Comparison
Compare CNTB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | MAIA |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 89.7M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CNTB | MAIA |
|---|---|---|
| Price | $2.90 | $1.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 193.2K | ★ 1.2M |
| Earning Date | 05-14-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.22 | 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $26,033,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17,706.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.87 |
| 52 Week High | $3.82 | $3.19 |
Technical Indicators
Market Signals| Indicator | CNTB | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 32.95 |
| Support Level | $2.16 | $1.26 |
| Resistance Level | $3.23 | $1.74 |
| Average True Range (ATR) | 0.33 | 0.08 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 29.76 | 13.85 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.